Log in
NASDAQ:TBPH

Theravance Biopharma Stock Forecast, Price & News

$17.82
+0.20 (+1.14 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$17.42
Now: $17.82
$17.88
50-Day Range
$16.61
MA: $17.88
$20.84
52-Week Range
$15.72
Now: $17.82
$31.54
Volume537,131 shs
Average Volume416,983 shs
Market Capitalization$1.14 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.44
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant. YUPELRI, a long-acting muscarinic antagonist, for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD); and Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders. The company's product candidates also comprise Selective 5-HT4 Agonist for treating gastrointestinal motility disorders; Gut-selective Pan-Janus Kinase Inhibitor Program for treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis; TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TD-0714 and Neprilysin Inhibitor Program, which have completed Phase I clinical studies for heart failure and chronic kidney disease, including diabetic nephropathy. In addition, it focuses on various drug development programs, including the combination of fluticasone furoate, umeclidinium bromide, and vilanterol for the treatment of COPD and asthma; the inhaled bifunctional muscarinic antagonist-beta2 agonist program, as monotherapy; and in combination with other therapeutically active components, such as an inhaled corticosteroid. The company was incorporated in 2013 and is based in George Town, the Cayman Islands.
Read More
Theravance Biopharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.48 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TBPH
Previous SymbolNASDAQ:TBPHV
CUSIPN/A
Phone650-808-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$73.41 million
Book Value($3.94) per share

Profitability

Net Income$-236,460,000.00
Net Margins-351.55%

Miscellaneous

Employees363
Market Cap$1.14 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$17.82
+0.20 (+1.14 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TBPH News and Ratings via Email

Sign-up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Theravance Biopharma (NASDAQ:TBPH) Frequently Asked Questions

How has Theravance Biopharma's stock been impacted by COVID-19 (Coronavirus)?

Theravance Biopharma's stock was trading at $24.80 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TBPH stock has decreased by 28.1% and is now trading at $17.82.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Theravance Biopharma?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Theravance Biopharma
.

When is Theravance Biopharma's next earnings date?

Theravance Biopharma is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Theravance Biopharma
.

How were Theravance Biopharma's earnings last quarter?

Theravance Biopharma Inc (NASDAQ:TBPH) issued its quarterly earnings data on Thursday, August, 6th. The biopharmaceutical company reported ($1.00) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.95) by $0.05. The biopharmaceutical company had revenue of $15.01 million for the quarter, compared to analyst estimates of $21.05 million.
View Theravance Biopharma's earnings history
.

What price target have analysts set for TBPH?

7 brokers have issued 1-year price targets for Theravance Biopharma's stock. Their forecasts range from $18.00 to $42.00. On average, they anticipate Theravance Biopharma's share price to reach $31.43 in the next twelve months. This suggests a possible upside of 76.4% from the stock's current price.
View analysts' price targets for Theravance Biopharma
.

Are investors shorting Theravance Biopharma?

Theravance Biopharma saw a increase in short interest during the month of August. As of August 14th, there was short interest totaling 2,970,000 shares, an increase of 11.7% from the July 30th total of 2,660,000 shares. Based on an average daily volume of 459,100 shares, the days-to-cover ratio is presently 6.5 days. Currently, 6.1% of the shares of the company are short sold.
View Theravance Biopharma's Short Interest
.

Who are some of Theravance Biopharma's key competitors?

What other stocks do shareholders of Theravance Biopharma own?

Who are Theravance Biopharma's key executives?

Theravance Biopharma's management team includes the following people:
  • Mr. Rick E. Winningham, Chairman & CEO (Age 59)
  • Mr. Bradford J. Shafer, Exec. VP, Gen. Counsel & Sec. (Age 59)
  • Dr. Shehnaaz Suliman M.D., M.Phil., M.B.A., Sr. VP of Corp. Devel. & Strategy (Age 46)
  • Dr. Brett K. Haumann, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 49)
  • Mr. Vijay Sabesan, Sr. VP of Technical Operations

What is Theravance Biopharma's stock symbol?

Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."

Who are Theravance Biopharma's major shareholders?

Theravance Biopharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.40%), Orbimed Advisors LLC (4.02%), Jane Street Group LLC (1.92%), Jacobs Levy Equity Management Inc. (0.77%), Peregrine Capital Management LLC (0.72%) and Goldman Sachs Group Inc. (0.53%). Company insiders that own Theravance Biopharma stock include Brett K Haumann, Donal O'connor, Philip D Worboys, Sharathchandra S Hegde and Vijay Sabesan.
View institutional ownership trends for Theravance Biopharma
.

Which major investors are selling Theravance Biopharma stock?

TBPH stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, Federated Hermes Inc., Nuveen Asset Management LLC, First Trust Advisors LP, SG Americas Securities LLC, Virtus ETF Advisers LLC, California State Teachers Retirement System, and State of Wisconsin Investment Board. Company insiders that have sold Theravance Biopharma company stock in the last year include Brett K Haumann, Philip D Worboys, and Vijay Sabesan.
View insider buying and selling activity for Theravance Biopharma
.

Which major investors are buying Theravance Biopharma stock?

TBPH stock was bought by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Jane Street Group LLC, Peregrine Capital Management LLC, Vanguard Group Inc., Hudson Bay Capital Management LP, Goldman Sachs Group Inc., Healthcare of Ontario Pension Plan Trust Fund, and Canada Pension Plan Investment Board.
View insider buying and selling activity for Theravance Biopharma
.

How do I buy shares of Theravance Biopharma?

Shares of TBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Theravance Biopharma's stock price today?

One share of TBPH stock can currently be purchased for approximately $17.82.

How big of a company is Theravance Biopharma?

Theravance Biopharma has a market capitalization of $1.14 billion and generates $73.41 million in revenue each year. The biopharmaceutical company earns $-236,460,000.00 in net income (profit) each year or ($4.25) on an earnings per share basis. Theravance Biopharma employs 363 workers across the globe.

What is Theravance Biopharma's official website?

The official website for Theravance Biopharma is www.theravance.com.

How can I contact Theravance Biopharma?

Theravance Biopharma's mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The biopharmaceutical company can be reached via phone at 650-808-6000 or via email at [email protected]

This page was last updated on 9/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.